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Introduction
Lung cancer screening programs with low-dose chest 
computed tomography in at-risk populations are resulting 
in increased numbers of patients with early-stage non-
small cell lung cancer (NSCLC) that is potentially best 
removed by minimally invasive surgical approaches (1). 
As a form of minimally invasive surgery, video-assisted 
thoracic surgery (VATS) has been recommended in 
patients with early-stage NSCLC (2). Video-assisted 
thoracoscopic lobectomy (VATL) showed acceptable and 
better postoperative outcomes in terms of postoperative 
pain, cosmetics, preservation of pulmonary function, and 
immunosuppression (3,4), and recent studies also showed 
that VATL showed equivalent oncologic outcomes to 
conventional open lobectomy (5). However, VATL has 
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several limitations such as its two-dimensional view and 
restrictive instrumental movement (6). 
Robotic surgery has advantages over VATS, including 
a steady camera with three-dimensional vision, wristed 
instruments, and improved ergonomics for the surgeon (6). 
Based on these advantages, robotic surgery has been 
introduced in certain fields of thoracic surgery such as 
mediastinal tumor excision, esophageal cancer, and lung 
cancer (7-10). As robotics can provide three-dimensional 
visualization and greater instrument maneuverability in a 
confined space, it has the potential of enhancing minimally 
invasive thoracoscopic lobectomy (11). In a previous study, 
robotic lobectomy for early-NSCLC was reported to be 
feasible and safe (8). In addition to the technical benefits 
of a robotic technique over VATS, the robotic system has 
another advantage in that conventional VATL requires an 
experienced endoscopist and assistant, whereas the surgeon 
can manipulate the scope and instruments alone in robotic 
surgery. Solo surgery can be defined as a practice in which 
a surgeon operates alone, without other surgical members 
except a scrub nurse (12). We hypothesized that a robotic 
system using the fourth arm of the da Vinci Robotic 
System could enable solo surgery without the need for an 
experienced endoscopist or assistant. In the surgical field, 
and especially in cardiothoracic surgery, the lack of human 
resources has been a problem, and we thought that solo 
surgery might be a solution to this obstacle. Therefore, 
this prospective study was performed to investigate the 
possibility and feasibility of the four-arm robotic lobectomy 
(FARL) technique as solo surgery in patients with early-
stage NSCLC. 
Methods
Patients and study design
We performed a prospective, patient-preference accrual 
study (IRB No. 1-2010-0054) that was planned in patients 
with clinical stage I NSCLC. The exclusion criteria were 
patients aged <20 years or >80 years, presence of hilar lesions, 
contraindication for one-lung ventilation, or severe pleural 
adhesion. The study period was March 2011 to February 
2013, and the patients chose between FARL and VATL as 
their preferred surgical technique. The study was designed 
with two stages. Interim analysis of early postoperative 
outcome was performed after the initial 10 cases in each 
group to test the feasibility and safety of the FARL technique. 
If the life-threatening complication rate was >10% or the 
thoracotomy conversion rate was >20%, we planned early 
termination of the study. Otherwise, we would continue the 
study with 10 additional cases per group. The 5-year overall 
survival and disease-free survival rates were calculated in both 
groups after completion of the study.
We collected data on the patients’ basic clinical 
characteristics (age, sex, preoperative pulmonary function, 
smoking history), operative outcomes [operation time, 
anesthesia time, blood loss, and number of dissected lymph 
nodes (LNs)], postoperative outcomes (complication, 
duration of chest tube drainage, and length of hospital stay), 
pathological data, and long-term oncologic outcomes. All 
procedures were performed by a surgeon who had already 
performed more than 200 VATL procedures prior to 
beginning the robotic lobectomy and who also had abundant 
experience with other robotic thoracic surgeries (13). 
Definitions
As an operative outcome, the lobectomy time was defined 
as time from the initiation of lobectomy to the retrieval of 
lung specimen. The anesthesia time was defined as time 
from the initiation of anesthesia to the finish of anesthesia 
after extubation. Life-threatening event was defined as 
any event that developed during the operation and was 
potentially fatal, such as injury of major vessel or bronchus. 
The operation time was defined as time from the skin 
incision to the closure of skin wound. Pain was assessed by 
nurses using a numeric pain visual analogue scale (VAS) 
every 8 hours and after interventions for pain control with 
intravenous analgesia. Prolonged air leakage was defined as 
leakage lasting beyond the 7th postoperative day (PODs) (14). 
Postoperative complications were recorded based on the 
Common Terminology Criteria for Adverse Events (CTC-AE) 
version 4.0 (15). Local recurrences were defined as those 
occurring on resection margins, such as bronchial stumps 
or stapler lines. Regional recurrences were defined as those 
occurring in the hilar or mediastinal LNs, pleural cavity, 
and ipsilateral lung. Distant recurrences were defined 
as those occurring in the contralateral lung, brain, liver, 
adrenal glands, bone, or other locations.
Surgical technique
All procedures were performed in the lateral decubitus 
position. VATL was performed using one working 
window and three thoracoscopic port incisions: 12 mm 
thoracoscopic port at 6th intercostal space (ICS) midaxillary 
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line, 12 mm port at the 5th ICS scapular tip, 5-mm port 
at the 3rd ICS midaxillary line, and 4 cm working window 
at the 5th ICS anterior axillary line (Figure 1A). One 
surgeon, one assistant, and one endoscopist participated 
in VATL. Robotic lobectomy was performed using the da 
Vinci Si system (Intuitive Surgical, Inc., Mountain View, 
CA) with the four-arm complete portal approach: 12 mm 
thoracoscopic port at the 8th ICS midaxillary line, 12 mm 
port at the 7th ICS posterior axillary line for the left arm, 
8 mm port at the 6th ICS scapular tip for the third arm, and 
8 mm port at the 6th ICS anterior axillary line for the right 
arm (Figure 1B). FARL was performed as a fully endoscopic 
procedure with CO2 inflation without a working window. 
For specimen retrieval, a small skin incision was made at 
the end of the operation. We used the double cannulation 
technique for the left arm, which uses an 8-mm port 
inserted in a 12 mm accessory port for maintain the CO2 
inflation during the operation (Figure 2A). For the insertion 
of robotic instruments, 8 mm trocar was inserted through 
the 12 mm port. For the retrieval of dissected LNs and 
insertion of gauze, 12 mm port was used after removing 
the 8 mm trocar (Figure 2B). The 5 mm thoracic grasper, 
8 mm curved bipolar dissector and fenestrated bipolar 
forceps were used for robotic procedure. One surgeon 
and one bed-side assistant participated in FARL. All 
procedures such as dissection, retraction of lung, and vessel 
isolation were performed by the surgeon, and the assistant 
played a minimal role, such as retrieval of dissected LNs 
and insertion of gauze. At the end of operation, we have 
expanded existing ports which located in anterior axillary 
line about 4 cm to be larger to retrieve the specimen if 
FARL group.
Figure 1 Port replacement in (A) video-assisted thoracoscopic lobectomy (VATL) and (B) four-arm robotic lobectomy. T, thoracoscopic 
port; L, port for left arm; R, port for right arm; 3rd, port for 3rd arm. 
A B
Figure 2 The double cannulation. (A) A 12 mm port was used for 
the retrieval of dissected lymph nodes (LNs) and insertion of gauze 
by assistant; (B) 8 mm trocar was inserted through the 12 mm port 
for inserting the robotic instruments. 
A B
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Statistical analysis
Patient general characteristics were described as mean ± 
standard deviation (SD) for continuous variables and as 
number of cases with frequency (%) for categorical variables. 
The two groups were compared using the Chi-square test 
or Fisher’s exact test for discrete variables and independent 
sample t-test for continuous variables. The Kaplan-Meier 
method and log-rank test were used to calculate and compare 
the survival rates. All P values were 2-sided, and P value 
<0.05 was considered significant. Statistical analysis was 
performed using the open-source statistical software R 
(http://www.R-project.org).
Results
Basic clinical characteristics
The study was terminated in September 2012 because the 
interim analysis demonstrated safety issues in the FARL 
group. Three cases (25%) of life-threatening events were 
observed in the FARL group; as a result, the study was 
terminated early after enrollment of 17 patients for the 
VATL group and 12 patients for the FARL group. The 
clinical characteristics of the study group are presented 
in Table 1. No significant differences were found between 
the two groups for sex, age, smoking history, preoperative 
pulmonary function, or clinical stage.
Operative outcomes and pathologic results
The operative outcomes are summarized in Table 2. 
Lobectomy time and total operation time (including LN 
dissection time) were significantly longer in the FARL 
group (VATL vs. FARL: 47.9±16.0 vs. 81.1±31.4 min for 
lobectomy time, P=0.009; 134.7±36.5 vs. 195.6±54.2 min 
for total operation time, P=0.003), whereas there was 
no significant difference in blood loss between the two 
groups (132.9±102.5 vs. 151.6±193.2 mL, P=0.738). Three 
life-threatening events (25.0%) occurred in the FARL 
group (1 bleeding from pulmonary artery, 1 bleeding from 
superior branches of pulmonary vein, and 1 bronchial 
tear), and one patient experienced emergent thoracotomy 
conversion in order to control bleeding from the superior 
pulmonary vein. The console surgeon performed anterior-
lateral thoracotomy by connecting the previously existed 
ports because the conventional posterolateral thoracotomy 
requires more time. In the patient who had pulmonary 
artery bleeding during right lower lobectomy, bleeding was 
controlled with FloSeal (Baxter International Inc., Vienna, 
Austria), and the total bleeding was 150 mL. Another 
patient had a right middle lobar bronchial tear during the 
right lower lobectomy and underwent repair of the RML 
bronchus with polydioxanone suture. The incidence of 
adverse events was not different between the two groups 
(P=0.297).
Pathological staging revealed that 14 patients in the 
VATL group (82.3%) had stage I, 2 (11.8%) had stage II, 
and 2 (11.8%) had stage IIIA cancer. In the FARL group, 11 
patients (86.7%) had stage I cancer and 1 (8.3%) had stage 
II cancer (P=0.646). There were no significant differences 
in histology and number of dissected LNs (22.9±13.0 vs. 
21.6±13.8, P=0.791).
Early postoperative outcome and pathological data
The early postoperative outcomes are summarized in Table 3. 
No significant differences in highest VAS score at each 
POD were observed between the groups on PODs 0, 1, 2, 
and 3 (VATL vs. FARL: 5.76±2.07 vs. 5.83±1.52, P=0.919; 
Table 1 Clinical characteristics of the study patients
Variables VATL (n=17) FARL (n=12) P value
Age (years) 61.2±10.9 62.6±7.2 0.679
Sex (%) 0.462
Male 7 (41.2) 7 (58.3)
Female 10 (58.8) 5 (41.7)
FEV1 (L) 106.9±17.9 106.8±15.4 0.987
Tumor location (%) 0.200
RUL 8 (47.1) 4 (33.3)
RML 1 (5.9) 0 (0.0)
RLL 4 (23.5) 2 (16.7)
LUL 3 (17.6) 1 (8.3)
LLL 1 (5.9) 5 (41.7)
Tumor size (cm) 2.2±0.8 1.9±0.8 0.283
Clinical stage (%) 0.970
IA 10 (58.8) 7 (58.3)
IB 7 (41.2) 5 (41.7)
VATL, video-assisted thoracic surgery lobectomy; FARL,  
four-arm robotic lobectomy; FEV1, forced expiratory volume in 
1 second; RUL, right upper lobe; RML, right middle lobe; RLL, 
right lower lobe; LUL, left upper lobe; LLL, left lower lobe.
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Table 2 Operative data
Variables VATL (n=17) FARL (n=12) P value
Pleural adhesion (%) 9 (52.9) 5 (41.7) 0.550
Lobectomy time (min) 47.9±16.0 81.1±31.4 0.009
Total operation time (min) 134.7±36.5 195.6±54.2 0.003
Anesthesia time (min) 205.6±34.8 295.4±54.3 <0.001
Blood loss (mL) 132.9±102.5 151.6±193.2 0.738
Life-threatening events (%) 0 3 (25.0) 0.06
Vascular injury 0 2* (16.7) 0.163
Bronchial tear 0 1 (8.3) 0.414
Histology (%) 0.163
Adenocarcinoma 17 (100.0) 10 (83.3)
Squamous cell carcinoma 0 (0.0) 2 (16.7)
Number of dissected lymph nodes 22.9±13.0 21.6±13.8 0.791
Visceral pleura invasion (%) 5 (24.5) 3 (25.0) 1.000
Pathological stage (%) 0.646
IA 11 (64.7) 8 (66.7)
IB 3 (17.6) 3 (25.0)
IIA 1 (5.9) 1 (8.3)
IIB 1 (5.9) 0 (0.0)
IIIA 2 (11.8) 0 (0.0)
*Superior pulmonary vein injury leading to thoracotomy conversion in 1 patient. VATL, video-assisted thoracoscopic lobectomy; FARL, 
four-arm robotic lobectomy.
Table 3 Early postoperative outcomes
Variables VATL (n=17) FARL (n=12) P value
Chest tube drainage duration (days) 3.9±1.9 5.2±4.1 0.326
Pain (highest VAS score)
POD 0 5.76±2.07 5.83±1.52 0.919
POD 1 5.47±1.90 5.42±2.42 0.949
POD 2 4.12±1.57 4.25±1.86 0.843
POD 3 4.41±2.42 3.75±1.71 0.397
Postoperative complication
Prolonged air leakage (%) 2 (11.8) 2 (16.7) 1.0
Length of hospital stay (days) 5.5±1.8 6.9±3.9 0.268
VATL, video-assisted thoracoscopic lobectomy; FARL, four-arm robotic lobectomy; VAS, visual analog scale; POD, postoperative day.
1612 Park et al. Robotic lobectomy as solo surgery for lung cancer
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2017;9(6):1607-1614jtd.amegroups.com
5.47±1.90 vs. 5.42±2.42, P=0.949; 4.12±1.57 vs. 4.25±1.86, 
P=0.843; 4.41±2.42 vs. 3.75±1.71, P=0.397, respectively). 
No significant differences were observed in duration of 
chest tube drainage (3.9±1.9 vs. 5.2±4.1 days, P=0.326) and 
length of hospital stay (5.5±1.8 vs. 6.9±3.9 days, P=0.268). 
Postoperative complications occurred in 2 (11.8%) patients 
in the VATL group and 2 (16.7%) patients in the FARL 
group (P=1.0). All complications were prolonged air 
leakage.
Recurrence and survival analysis
The mean follow-up time was 48.9±9.5 months. Recurrence 
was detected in 2 (16.7%) patients after FARL and in 
3 (23.5%) patients after VATL (P=0.671). In the VATL 
group, 2 (16.7%) patients had locoregional recurrence: one 
in the ipsilateral lung and one in the pleura. Three (23.5%) 
patients in the FARL group suffered from recurrences: one 
in the ipsilateral lung and two pleural masses. The 5-year 
overall survival was 100% in the FARL group and 87.5% 
in the VATL group (log-rank test, P=0.386, Figure 3A), and 
5-year disease-free survival was 82.5% in the FARL group 
and 75.6% in the VATL group (log-rank test, P=0.589, 
Figure 3B). The overall and disease-free survival rates were 
comparable between the two groups.
Discussion
VATL has been recommended for early-stage NSCLC (2) 
because it showed acceptable or better postoperative 
outcomes as well as equivalent long-term survival in 
comparisons with conventional open lobectomy (3-5). 
Recently, robotic lobectomy has been introduced because 
the robotic system can offer advantages such as three-
dimensional vision, wristed instruments, and improved 
ergonomics for the surgeon (16). Many studies have 
reported the feasibility and safety of robotic-assisted 
thoracoscopic lobectomy. Jang et al. showed that the 
outcome of robot-assisted surgery was significantly more 
favorable than that of VATL in terms of postoperative 
complications, intraoperative blood loss, and postoperative 
length of hospital stay (8). Louie et al. reported that the 
robotic lobectomy group used fewer analgesics and returned 
to daily activities earlier than the VATS group, although no 
significant difference in perioperative outcomes was found 
between the two groups (9).
The VATS procedure requires  an experienced 
endoscopist and assistant. The visual information is 
collected by a camera assistant, who controls the endoscope 
based on the surgeon’s instructions and using a set of 
empirical rules. This can lead to communication problems 
between the surgeon and the assistant and to an unsteady 
camera picture when the assistant has to stand still for a 
long time (12). The previous settings for conventional 
robotic lobectomy usually require an experienced bedside 
surgeon for retraction of the lung, suctioning of retained 
blood, and stapling. For example, in Louie’s report, the first 
30 pulmonary resections used 2 attending surgeons (one 
on the console and one at the bedside); after 30 cases, a 
thoracic surgery fellow was used as the bedside assistant (9). 
The need for two surgeons in one robotic operation is 
excessive use of medical personnel. We proposed that 
the surgeon at the console could manipulate both the 
instruments and the camera. Therefore, we planned 
complete robotic lobectomy as a solo surgery, without an 
experienced endoscopist or assistant. Solo surgery has been 
defined as a practice in which a surgeon operates alone, 
without other surgical members except a scrub nurse (12). 
Figure 3 Survival curves. (A) Five-year overall survival; (B) disease-free survival.
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We thought that solo surgery might provide a solution to 
the worldwide lack of human resources in the surgical field, 
especially in cardiothoracic surgery. Our main reason for 
using the robotic system in lobectomy was to minimize the 
utilization of medical personnel. Therefore, we performed 
this study to investigate the feasibility and efficacy of FARL 
as a solo surgery in NSCLC.
In our study, we compared operative, postoperative, and 
survival data between FARL and VATL. Even though FARL 
and VATL showed similar operative outcomes and long-term 
oncologic outcomes, FARL required longer operation time 
and anesthesia time. Robotic surgery is useful because a 
high-resolution three-dimensional monitor and flexible 
instruments provide a wrist-like motion that enables 
meticulous dissection in a narrow space, such as recurrent 
laryngeal nerve nods in esophageal cancer (7). During the 
procedure, we realized that the benefits of robotic surgery 
were not as prominent as expected because lobectomy with 
mediastinal LN dissection is a multi-quadrant surgery. In 
addition, the incidences of life-threatening events were 
more frequent in FARL group, although with marginal 
significance (P=0.06). A possible explanation for this is the 
difficulty in dissecting the posterior part of a target tissue 
such as vessels of bronchi because of the lack of tactile 
feedback. In addition, adequate exposure of the operation 
field was sometimes difficult because retraction of the lung 
with the fourth arm was cumbersome. Also, the current 
robotic system does not allow simultaneous action of both 
the third arm and the fourth arm. Those issues seemed to 
contribute to the prolonged operation time in FARL, which 
was significantly longer than that of VATL in our study; the 
FARL procedure was typically 1 hour longer than VATL. 
Although we introduced FARL to reduce the use of medical 
personnel, the total use of resources might be increased 
because of the prolonged operation time. Another drawback 
of FARL is that it is very expensive. In the national health 
insurance system of our county, the patient usually pays 
4,000 US dollar after VATL including hospitalization, 
compared with 12,000 US dollars after FARL. Considering 
the high cost of robotic surgery and the outcome data, 
we thought that the transition from VATL to FARL by a 
surgeon who is already experienced in VATL could not 
be recommended because of safety issues and economic 
reasons. The similar results were reported in recent article; 
Migliore mentioned that the adoption of the robotic system 
in pulmonary resection is problematic due to no survival 
benefits, longer duration of the operation and the longer 
operative room usage and higher cost compared to open or 
VATS lobectomy (17).
This study has several limitations. First, this study 
enrolled too few patients because the study was terminated 
early due to safety issues. The second involves the issue of a 
learning curve for FARL; however, our surgeon had already 
performed more than 200 cases of robotic surgery, including 
esophagectomy and mediastinal tumor excision (13).
In conclusion, this study showed that FARL as a solo 
surgery failed to demonstrate any benefits over VATL. 
Considering the safety issues and high cost of robotic 
surgery, the transition from VATL to FARL may not be 
recommended for experienced surgeons.
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